Hong Kong Stock Movers: CARSGEN-B (02171) Rises Over 9% Against the Market as Kailimei Becomes the First Solid Tumor CAR-T Product Included in the Commercial Insurance Innovative Drug List

Stock News10:36

CARSGEN-B (02171) rose more than 9% against the broader market trend. As of press time, the stock was up 7.08% at HK$10.74, with turnover of HK$19.8707 million.

On the news front, on November 14, the 2026 Commercial Health Insurance Innovative Drug List was announced. CARSGEN's Kailimei® (sureucabtagene autoleucel injection) was included in the Commercial Insurance Innovative Drug List, becoming the first solid tumor CAR-T cell therapy product to be included since the establishment of the list.

Public information shows that Kailimei® is the world's first-in-class autologous CAR-T cell therapy product targeting the Claudin18.2 protein, and also the world's first approved and marketed solid tumor CAR-T cell therapy product. The drug was approved for marketing by the National Medical Products Administration in June 2026 for the treatment of Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) that has failed at least second-line therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment